Androgen deprivation therapy and cardiovascular risk
Rees, J.
Practitioner 259(1785): 5
2015
ISSN/ISBN: 0032-6518 PMID: 26591651 Document Number: 681607
Document emailed within 1 workday
Related Documents
Buyyounouski, M.K. 2010: Androgen deprivation therapy in high-risk prostate cancer Oncology 24(9): 806; 8092015: (P063) Can Some High-Risk Prostate Cancer Patients Be Treated With a Shorter Course of Androgen Deprivation Therapy (ADT)? Oncology 29(4 Suppl. 1)
Pickles, T.; Pollack, A. 2006: The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancer Canadian Journal of Urology 13(Suppl 2): 68-71
Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T.; Kallioniemi, O.P. 1997: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Research 57(2): 314-319
Arai, G.; Okada, H. 2016: Androgen deprivation therapy for prostate cancer: adverse effects and their management Nihon Rinsho. Japanese Journal of Clinical Medicine 74(Suppl 3): 605-609
2006: Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy Journal of Supportive Oncology 4(2): 99-100
Soloway, M.S. 1990: The importance of pretreatment testosterone and other prognostic variables in the response to androgen deprivation therapy Progress in Clinical and Biological Research 350: 141-148
Ying, J.; Yao, D.-H.; Ren, X.-M. 2003: Study of sexual hormone changes in prostate cancer patients before and after androgen deprivation therapy Zhonghua Nan Ke Xue 9(3): 191-192; 196
Alvarez Rodríguez, S.; Alonso Gordoa, T.; Burgos Revilla, F.Javier. 2018: Current status of androgen deprivation therapy in hormone-sensitive prostate cancer Archivos Espanoles de Urologia 71(3): 247-257
Ziaran, S.; Goncalves, F.M.; Wendl, J.; Trebaticky, B.; Breza, J.S. 2009: Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy Bratislavske Lekarske Listy 110(9): 559-562
Rentsch, C.A.; Aebersold, D.M.; Merz, V.; Studer, U.E. 2005: Cancer of the prostate: importance of androgen deprivation and radiotherapy Revue Medicale Suisse 1(19): 1303-1306
Blank, K.R.; Whittington, R.; Arjomandy, B.; Wein, A.J.; Broderick, G.; Staley, J.; Malkowicz, S.B. 1999: Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: smaller volumes, less morbidity Cancer Journal From Scientific American 5(6): 370-373
Tiwari, S.; Gupta, S.K.; Mehrotra, M.; Agarwal, G.; Awasthi, P.K.; Godbole, M.M. 2002: Short-term androgen deprivation does not alter CaR and VDR mRNA expression in duodenal mucosa in male rats Indian Journal of Experimental Biology 40(7): 780-784
Greco, C.; Castiglioni, S.; Fodor, A.; Mazzetta, C.; De Cobelli, O.; Orecchia, R. 2004: Androgen ablation therapy does not increase the risk of late morbidity following 3D-conformal radiotherapy of organ-confined prostate cancer: the experience of the European Institute of Oncology Tumori 90(6): 567-572
Baena Díez, Jé.Miguel.; Del Val García, Jé.Luis.; Alemany Vilches, L.; Martínez Martínez, Jé.Luis.; Tomàs Pelegrina, J.; González Tejón, Ián.; Raidó Quintana, E.María.; Rovira España, Mónica. 2005: Risk of Suffering from Cardiovascular Diseases because of the Clustering of the Modifiable Cardiovascular Risk Factors in the Population Older than 15 years of a Health Care Center in Barcelona Revista espanola de salud publica 79: 365-378
Kleber, M.E.; Winkler, K.; Wolfert, R.L.; Delgado, G. de Moissl; Grammer, T.B.; Dietz, S.; Winkelmann, B.R.; Boehm, B.O.; Winfried März 2011: Lipoprotein Associated Phospholipase A2 Concentration Predicts Total and Cardiovascular Mortality Independently of Established Risk Factors (The Ludwigshafen Risk and Cardiovascular Health Study) Clinical Laboratory 57(9-10): 659-667
Osler, M.; Jespersen, N.B.; Lous, J.; Rasmussen, N.K. 1992: Cardiovascular risk factors--extent and self-assessed risk in relation to prevention of cardiovascular diseases. A questionnaire among 3,956 men and women aged 24-65 years in Vejle County, Slangerup and Helsinge municipalities Ugeskrift for Laeger 154(9): 538-543
VandeKieft, G. 1996: Postmenopausal hormone therapy and cardiovascular risk Journal of Family Practice 43(5): 437-438
Perna, A. 2008: Folate therapy for prevention of cardiovascular risk in uremia Giornale Italiano di Nefrologia: Organo Ufficiale Della Societa Italiana di Nefrologia 25(3): 273
Smith, S.C. 1997: The challenge of risk reduction therapy for cardiovascular disease American Family Physician 55(2): 491-500